Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials

Cervical cancer is preventable and treatable, yet remains a significant global health burden. In 2020, it was the fourth most diagnosed cancer and the fourth leading cause of cancer-related deaths in women [1]. The burden of disease is disproportionally felt by low- and middle-income countries (LMICs), with highest incidence and mortality rates occurring in Africa, Melanesia, South America, South East Asia, and South Central Asia (age-standardized rate per 100,000: incidence, 15.3-40.1; mortality, 7.8-28.6) [1].

Source: Cancer Treatment Reviews - April 1, 2022 Category: Cancer & Oncology Authors: Bradley J. Monk, Takayuki Enomoto, W. Martin Kast, Mary McCormack, David S. P. Tan, Xiaohua Wu, Antonio Gonz ález-Martín Source Type: research